Added to YB: 2026-07-13
Pitch date: 2026-07-09
LQDA [neutral]
Liquidia Corporation
-3.3%
current return
Author Info
Value with a Catalyst covers long value oriented small and mid- cap investment ideas with a catalyst. Sign up for the newsletter.
Company Info
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States.
Market Cap
$6.9B
Pitch Price
$80.59
Price Target
N/A
Dividend
N/A
EV/EBITDA
143.84
P/E
319.22
EV/Sales
23.93
Sector
Pharmaceuticals
Category
special_situation
Liquidia - Potential Takeout Valuations
LQDA (overview): Yuvanki/Treprostinil biotech, $7B mkt cap. Takeout scenarios at 4x est peak sales: $98/sh (50% share, $2.2B sales), $137/sh (70% share, $3B), $314/sh (market expansion, likely too big at $27.5B). Legal risk post-Hikma easing. Market prices ~50% share; upside needs continued UTHR share gains, L606 progress, market expansion. Now large for typical biotech M&A.
Read full article (4 min)